141
Participants
Start Date
December 11, 2023
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2027
ONC-392 low
ONC-392 will be given as IV infusion, Q4W for up to 13 doses.
ONC-392 high
ONC-392 will be given as IV infusion, Q6W for up to 9 doses.
lutetium Lu 177 vipivotide tetraxetan
lutetium Lu 177 vipivotide tetraxetan will be given as IV infusion, Q6W, for up to 6 doses.
RECRUITING
NYU Langone Health, Laura & Isaac Perlmutter Cancer Center, New York
RECRUITING
Columbia University Irving Cancer Center, New York
RECRUITING
Roswell Park Comprehensive Cancer Center, Buffalo
RECRUITING
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
RECRUITING
Chesapeake Urology Research Associates, Towson
RECRUITING
Virginia Cancer Specialists USOR, Fairfax
RECRUITING
Virginia Oncology Associates USOR, Norfolk
RECRUITING
Oncology and Hematology Associates Of Southwest Virginia USOR, Norton
RECRUITING
UNC North Carolina Comprehensive Cancer Care Center, Chapel Hill
RECRUITING
Duke Cancer Center, Durham
RECRUITING
Emory University Winship Cancer Institute, Atlanta
RECRUITING
Moffitt Cancer Cancer, Tampa
RECRUITING
University of Mississippi Medical Center, Jackson
RECRUITING
The Ohio State University Comprehensive Cancer Center, Columbus
RECRUITING
UW Carbone Cancer Center, Madison
RECRUITING
XCancer/GU Research Network, Omaha
RECRUITING
UT Southwestern Medical Center, Dallas
RECRUITING
Rocky Mountain Cancer Centers USOR, Aurora
RECRUITING
New Mexico Oncology Hematology Consultants, Albuquerque
RECRUITING
UC Davis Comprehensive Cancer Center, Sacramento
RECRUITING
OHSU Knight Cancer Institute, Portland
RECRUITING
Lahey Hospital & Medical Center, Burlington
RECRUITING
Rutgers Cancer Institute, New Brunswick
Prostate Cancer Clinical Trials Consortium
OTHER
OncoC4, Inc.
INDUSTRY